CTRI Number |
CTRI/2020/03/023783 [Registered on: 05/03/2020] Trial Registered Prospectively |
Last Modified On: |
21/09/2021 |
Post Graduate Thesis |
No |
Type of Trial |
Observational |
Type of Study
|
Cross Sectional Study |
Study Design |
Non-randomized, Active Controlled Trial |
Public Title of Study
|
A study of a safe and non-invasive method for preventive screening for breast cancer and monitoring of breast cancer patients. |
Scientific Title of Study
|
A prospective study to evaluate the effectiveness of Thermalytixâ„¢ (AI-based thermographic screening solution) for preventive screening, diagnosis, and monitoring of breast cancer patients. |
Trial Acronym |
SANT20 |
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIR-RCC-THERMAL Version 1.0 Dated Jan 10th 2019 |
Protocol Number |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Venugopal M |
Designation |
Professor and Head of Department |
Affiliation |
Regional Cancer Center (RCC), Thiruvananthapuram |
Address |
Department of Radiodiagnosis,
Regional Cancer Centre,
Medical College Campus,
Post Bag No.2417,
Thiruvananthapuram
Thiruvananthapuram KERALA 695011 India |
Phone |
9349981765 |
Fax |
|
Email |
drvenurcc@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Dr Venugopal M |
Designation |
Professor and Head of Department |
Affiliation |
Regional Cancer Center (RCC), Thiruvananthapuram |
Address |
Department of Radiodiagnosis,
Regional Cancer Centre,
Medical College Campus,
Post Bag No.2417,
Thiruvananthapuram
Thiruvananthapuram KERALA 695011 India |
Phone |
9349981765 |
Fax |
|
Email |
drvenurcc@gmail.com |
|
Details of Contact Person Public Query
|
Name |
Dr Geetha Manjunath |
Designation |
Chief Executive Officer |
Affiliation |
NIRAMAI Health Analytix Pvt Ltd |
Address |
A7-506, Elita Promenade,
J P Nagar 7th Phase,
Bangalore
Bangalore KARNATAKA 560078 India |
Phone |
9880118379 |
Fax |
|
Email |
geetha@niramai.com |
|
Source of Monetary or Material Support
|
NIRAMAI Health Analytix Pvt Ltd, A7-506, Elita Promenade, JP Nagar 7th Phase, Bangalore - 560078 |
|
Primary Sponsor
|
Name |
NIRAMAI Health Analytix Pvt Ltd |
Address |
A7 506, Elita Promenade, J P Nagar, 7th Phase
Bengaluru – 560078 Karnataka, India |
Type of Sponsor |
Other [Health Technology Company] |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Venugopal M |
Regional Cancer Centre (RCC), Trivandrum |
Department of Radiodiagnosis, Level 2, A2 23, Medical College Campus,
Post Bag No 2417,
Thiruvananthapuram,
India – 695011 Thiruvananthapuram KERALA |
9349981765
drvenurcc@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Human Ethics Committee, RCC |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
Nil |
Nil |
Intervention |
Nil |
Nil |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
80.00 Year(s) |
Gender |
Female |
Details |
1. Women presenting with or without symptoms of breast cancer
2. Women with previous history of breast cancer or currently undergoing treatment for breast cancer who present for follow-up
3. Women who are willing to give written informed consent for study participation
4. Women who are ready to comply with the study related visits and procedures |
|
ExclusionCriteria |
Details |
1. Subjects who are pregnant
2. Subjects who are lactating
3. Subjects who have undergone Chemotherapy in the last 2 weeks at the time of study enrollment
4. Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator |
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Investigator Blinded |
Primary Outcome
|
Outcome |
TimePoints |
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Thermalytix in asymptomatic and symptomatic women who have not been diagnosed earlier for breast cancer |
Every 6 months for 3 years |
|
Secondary Outcome
|
Outcome |
TimePoints |
Performance of Thermalytix in women previously diagnosed with breast cancer. |
Every 6 months for 3 years |
Influence of patient characteristics on diagnostic accuracy of Thermalytix©.
Patient characteristics will include:
(a) Age
(b) Lesion type
(c) Pathologic diagnosis
(d) Menopausal and hormonal status
(e) Breast density
(f) Family history
(g) Other risk factors |
3 years |
Recommend how Thermalytix can be used to complement standard breast cancer screening procedure |
3 years |
|
Target Sample Size
|
Total Sample Size="3000" Sample Size from India="3000"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
09/03/2020 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="3" Months="6" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Open to Recruitment |
Recruitment Status of Trial (India) |
Open to Recruitment |
Publication Details
Modification(s)
|
Nil |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
Modification(s)
|
Cancer of the breast is the most common cause of cancer-related death in India. Detecting breast cancer at early stages is crucial for providing treatment and reducing disease morbidity and mortality. Mammography is the only known method to reduce breast cancer mortality. However, mammography has certain limitations. It is not recommended to be used on women under the age of 45 years, cannot be used on lactating/pregnant women, is less effective on women with high density of breast, and repeated mammography comes with a risk of radiation-induced breast cancer. Mammography in correlation with sono-mammography is widely used currently for screening in hospitals. Infrared imaging of the breast or thermography is an imaging technique which detects suspected malignancy based on thermal changes on the chest. Due to increased blood circulation and metabolic activity of the tumour, the temperature of the tumour tissue is higher than the surrounding areas. This thermal information is captured by a high-resolution thermal camera. A thermal image provides a visual representation of the temperature distribution and can be used for clinical interpretation of abnormal breast conditions as an adjunct modality. Certain trained clinicians who are certified thermologists can interpret these breast thermograms to determine its malignancy or benign condition. However, manual interpretation of these thermograms is very cumbersome and error prone. Thermalytixâ„¢, a novel artificial intelligence and machine learning-based CAD system, is a new method of interpreting thermal images that has shown higher sensitivity and comparable specificity when compared with mammography in early experiments. Thermalytixâ„¢ is a non-contact, non-invasive, radiation-free, affordable and is also applicable to women under 45 years and those with dense breasts. In this study, the entry criteria for the study will be asymptomatic women, symptomatic women who show possible symptoms of suspected breast cancer, such as pain, lump and so on, and women who come for follow-up after diagnosis/treatment of breast cancer. The primary objectives of the study are to assess a non-inferiority of sensitivity of Thermalytixâ„¢ over the sensitivity of standard screening procedures by not more than 10% and study comparative diagnostic performance of Thermalytixâ„¢ with standard screening modalities in asymptomatic and symptomatic women. The endpoint measurements would be sensitivity, specificity, PPV, and NPV in the detection of breast cancer in women without an earlier history of breast cancer. The secondary objectives include evaluating the performance of Thermalytixâ„¢ in women previously diagnosed with breast cancer, study the influence of effects of patient characteristics on diagnostic accuracy and the evaluation of changes in Thermalytix scores of women who come for follow-up after diagnosis or treatment of breast cancer across various visits. Also, Thermalytixâ„¢ as a complement to the standard modalities in breast cancer will be evaluated. A publication at the end of each year will be targeted. This protocol for human research study will be conducted according to standards of effective Good Clinical Practice (International Conference on Harmonization [ICH] Guidelines), applicable Indian regulations and applicable Ethical Guidelines for Biomedical Research involving Human Participants issued by the Indian Council of Medical Research. The trial protocol and study participant documentation were reviewed and approved by the Institutional Ethical Review Boards of the participating trial site. |